Pharmaceutical Biocatalysis pdf

Peter Grünwald heads the machine learning group at CWI in Amsterdam, the Netherlands. He is also full professor of Statistical Learning at the mathematical institute of Leiden University. Currently the President of the Association for Computational Learning, the organization running COLT, the world’s prime annual conference on machine learning theory, he was co-program chair of COLT in 2015 and also chaired UAI – another top ML conference – in 2010/2011. Apart from publishing at ML venues like NIPS, COLT and UAI, he also regularly contributes to statistics journals such as the Annals of Statistics. He is the author of the book The Minimum Description Length Principle, (MIT Press, 2007; see here for an up-to-date (2020), much shorter introduction), which has become the standard reference for the MDL approach to learning. In 2010 he was co-awarded the Van Dantzig prize, the highest Dutch award in statistics and operations research. He received NWO VIDI (2005), VICI (2010) and TOP-1 (2016) grants.

Pharmaceutical Biocatalysis pdf by Peter Grünwald

This book provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, rare diseases, orphan drugs, the costs of drug development and therapies, and enzymes in downstream processing of pharmaceuticals. It discusses carbonic anhydrase inhibitors and their multiple drug interactions, carboxylesterase inhibitors for pharmaceutical applications, employment of inhibitors for the treatment of neurodegenerative diseases, use of engineered proteins, bioactive peptides, and fibrinolytic enzymes for thrombolytic therapy, and enzymes important for the design and development of new drugs/drug metabolites such as aldehyde oxidases and cytochrome P450 enzymes and the role the latter play in vascular biology and pathophysiology. The treatment of cancer is explored in connection with enzymatic amino acid deprivation therapies and new drugs that act as chemical degraders of oncogenic proteins. The book also introduces the resistance mechanisms of cancer. Furthermore, it provides an insight into the relationship between pathological conditions of cardiovascular disease and oxidative stress. The text also focuses on the potential use of nanoparticles as carriers for enzymes with medical relevance, computer-aided drug design for the identification of multi-target directed ligands, and the development of improved therapeutics through a glycan-“designer” approach. It concludes with an introduction to the chemoenzymatic synthesis of drugs.